Industry Verticals »

All Categories

Insights »

About TMR »

Kaposi Sarcoma Market

Kaposi Sarcoma Market (Treatment - Chemotherapy (Liposomal Anthracyclines, Alkaloids), Immunotherapy, HAART); Distribution Channel - Hospitals, Cancer Research Institutes, Multispecialty Clinics,Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Kaposi Sarcoma Market: Snapshot

Kaposi sarcoma (KS) refers to a type of cancer that develops from the cells lining blood vessels or lymph nodes. The cancer usually appears as tumors on mucosal surfaces or on the skin, but can also develop in body parts such as the digestive tract, or the lungs. The abnormal KS cells cause brown, purple, or red blotches on the skin, called lesions.

The global Kaposi sarcoma market features a rising number of regional vendors commanding prominent shares in their respective regional territories. Owing to the looming patent expiries of several blockbuster drugs, the market is expected to witness the entry of several new companies producing generics. The situation also presents immense growth opportunities for leading companies with new drug formulations in the next few years.

Transparency Market Research states that the global Kaposi sarcoma market will exhibit a modest 2.2% CAGR over the period between 2016 and 2024, rising from a valuation of US$118.5 mn in 2015 to US$143.2 mn by 2024.

 

kaposi-sarcoma-market

 

Chemotherapy Continues to Remain Most Preferred Course of Treatment despite High Cost

The key treatment methods for Kaposi sarcoma include immunotherapy, chemotherapy, and antiretroviral therapy. Of these, the segment of antiretroviral therapy emerged at the leading segment owing to the high incidence rate of AIDS-related Kaposi sarcoma. The segment will continue to grow at an encouraging pace in the next few years as well.

Over the report’s forecast period, however, the segment of chemotherapy is expected to exhibit growth at the most promising pace, chiefly owing to the high treatment cost and the high preference given to the treatment method by immunocompetent patients. Some of the most popular chemotherapy drugs in the market are vincristine, docetaxel, paclitaxel, bleomicin, daunorubicin, and liposomal doxorubicin. Although the high preference to this treatment method, its high cost could emerge as a key deterrent to patient population across some regions, especially across developing and less developed economies across Asia Pacific and Africa, limiting its growth prospects. 

North America to Retain Dominance in Global Market despite a Low Rate of Prevalence of Kaposi Sarcoma

From a geographical standpoint, North America is presently the leading contributor of revenue to the global Kaposi sarcoma market. The region holds a leading position in the global market owing to the presence of some of the world’s leading vendors in the field and the rising costs of drugs. The North America market for Kaposi sarcoma also benefits from the high rate of diagnosis of the condition and the easy availability of drugs. The region features a low incidence rate of the disease but has been witnessing a shortage in supply of drugs required for its treatment, leading to a wide demand-supply gap and subsequently significant scope of growth.

Over the report’s forecast period, the market is expected to witness the most promising rate of growth in the Middle East and Africa region. The region is expected to lead to the heightened demand for Kaposi sarcoma drugs owing to the high rate of incidence of the disease. The high rate of prevalence of HIV/AIDS is and thus the increased prevalence of AIDS induced Kaposi sarcoma in Eastern Africa is also a key driving factor, along with the fact that awareness among people is low.

Some of the leading players operating in the immensely consolidated vendor landscape of the global Kaposi sarcoma market are Johnson & Johnson, Merck & Co., Inc., Bristol Myers Squibb, Hoffman-La Roche, Inc., Pfizer, Inc., GlaxoSmithKline plc, and Eli Lilly and Co.

Alarming Rise in Cancer Cases to Accelerate the Growth of the Kaposi Sarcoma Market

Cancer has affected many people around the globe. Various cancer types are responsible for a large number of fatalities across the world. Kaposi Sarcoma is one of them. The rising prevalence of Kaposi Sarcoma across many individuals will serve as a prominent growth-generating factor for the global Kaposi Sarcoma market during the assessment period of 2016-2024.

  • Kaposi Sarcoma is a soft-tissue cancer type. It is a cancer that begins in the tissue that connects and supports the body. The cancer is generally located under the skin surface or in the nose and mouth lining. The cancer is caused due to a virus known as human herpesvirus 8. In this cancer type, patches of abnormal tissues grow under the skin and other organs. These patches are red or purple in color. Patients having weakened immune systems due to AIDS or prescribed drugs generally result in the development of Kaposi Sarcoma.
  • The escalating number of cases across the globe related to Kaposi Sarcoma will serve as a vital growth factor for the Kaposi Sarcoma market during the forecast period of 2016-2024. The ongoing research and development activities around the world will serve as a significant growth-contributor. These activities result in formulations that help in increasing the efficacy and quality of Kaposi Sarcoma drugs. Mergers and acquisitions also play a crucial role in the growth of the Kaposi Sarcoma market.
  • The novel coronavirus pandemic has a minimal effect on the growth of the Kaposi Sarcoma market. The healthcare sector was exempted from the strict lockdown restrictions. The demand for Kaposi Sarcoma drugs was down considerably due to low diagnosis on the back of the scant footfall in clinics and hospitals. The virus spread panic is a prominent reason. The mass vaccination drives across numerous countries will bring considerable growth opportunities for the players in the Kaposi Sarcoma market.

    1. Preface
         1.1. Market Definition and Scope
         1.2. Market Segmentation
         1.3. Key Research Objectives
         1.4. Research Highlights   

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Kaposi sarcoma market

    4. Market Overview
         4.1. Introduction 
         4.2. Key market indicators
         4.3. Regulatory scenario
         4.4. Market Dynamics
                4.4.1. Drivers
                4.4.2. Restraints
                4.4.3. Opportunities
         4.5. Value Chain Analysis

    5. Global Kaposi Sarcoma Market, by Treatment 
         5.1. Key Findings 
         5.2. Global Kaposi Sarcoma Market, by Type of Treatment, (US$ Mn), 2014–2024
                5.2.1. Chemotherapy
                        5.2.1.1. Liposomal Anthracyclines
                        5.2.1.2. Alkaloids
                5.2.2. Immunotherapy
                5.2.3. HAART
         5.3. Global Kaposi Sarcoma Market Attractiveness, by Treatment, 2015

    6. Global Kaposi Sarcoma Market, by Distribution Channel
         6.1. Global Kaposi Sarcoma Market, by Distribution Channel, (US$ Mn), 2014–2024
                6.1.1. Hospitals
                6.1.2. Cancer Research Institutes
                6.1.3. Multispecialty Clinics
                6.1.4. Ambulatory Surgical Centers
         6.2. Global Kaposi Sarcoma Market Attractiveness, by Distribution Channel, 2015

    7. Global Kaposi Sarcoma Market, by Region
         7.1. Global Kaposi Sarcoma Market, by Region, (US$ Mn), 2014–2024
                7.1.1. North America
                7.1.2. Europe
                7.1.3. Asia Pacific
                7.1.4. Latin America
                7.1.5. Middle East and Africa
         7.2. Global Kaposi Sarcoma Market Attractiveness, by Region, 2015

    8. Global Kaposi Sarcoma Market, Pipeline Analysis 
         8.1. Overview
         8.2. List of Early Stage Drug Candidates 

    9. North America Kaposi Sarcoma Market
         9.1. North America Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
                9.1.1. Chemotherapy 
                9.1.2. Immunotherapy 
                9.1.3. HAART
         9.2. North America Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
                9.2.1. Hospitals
                9.2.2. Cancer Research Institutes
                9.2.3. Multispecialty Clinics
                9.2.4. Ambulatory Surgical Centers
         9.3. North America Kaposi Sarcoma Market, by Country, (US$), 2014–2024
                9.3.1. U.S.
                9.3.2. Canada
         9.4. Market Attractiveness, by Type of Treatment, 2015
         9.5. Market Attractiveness, by Country, 2015

    10. Europe Kaposi Sarcoma Market
         10.1. Europe Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
                10.1.1. Chemotherapy 
                10.1.2. Immunotherapy 
                10.1.3. HAART
         10.2. Europe Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
                10.2.1. Hospitals
                10.2.2. Cancer Research Institutes
                10.2.3. Multispecialty Clinics
                10.2.4. Ambulatory Surgical Centers
         10.3. EuropeKaposi Sarcoma Market, by Country, (US$), 2014–2024
                10.3.1. U.K.
                10.3.2. Germany
                10.3.3. Rest of Europe
         10.4. Market Attractiveness, by Type of Treatment, 2015
         10.5. Market Attractiveness, by Country, 2015

    11. Asia Pacific Kaposi Sarcoma Market
         11.1. Asia Pacific Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
                11.1.1. Chemotherapy 
                11.1.2. Immunotherapy 
                11.1.3. HAART
         11.2. Asia Pacific Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
                11.2.1. Hospitals
                11.2.2. Cancer Research Institutes
                11.2.3. Multispecialty Clinics
                11.2.4. Ambulatory Surgical Centers
         11.3. Asia Pacific Kaposi Sarcoma Market, by Country, (US$), 2014–2024
                11.3.1. China
                11.3.2. Japan
                11.3.3. India
                11.3.4. Australia
                11.3.5. Rest of Asia Pacific
         11.4. Market Attractiveness, by Type of Treatment, 2015
         11.5. Market Attractiveness, by Country, 2015

    12. Latin America Kaposi Sarcoma Market
         12.1. Latin America Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
                12.1.1. Chemotherapy 
                12.1.2. Immunotherapy 
                12.1.3. HAART
         12.2. Latin America Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
                12.2.1. Hospitals
                12.2.2. Cancer Research Institutes
                12.2.3. Multispecialty Clinics
                12.2.4. Ambulatory Surgical Centers
         12.3. Latin America Kaposi Sarcoma Market, by Country, (US$), 2014–2024
                12.3.1. Brazil
                12.3.2. Mexico
                12.3.3. Rest of Latin America
         12.4. Market Attractiveness, by Type of Treatment, 2015
         12.5. Market Attractiveness, by Country, 2015

    13. Middle East and Africa Kaposi Sarcoma Market
         13.1. Middle East and Africa Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
                13.1.1. Chemotherapy 
                13.1.2. Immunotherapy 
                13.1.3. HAART
         13.2. Middle East and Africa Kaposi Sarcoma Market, by Distribution Channel, (US$), 2014–2024
                13.2.1. Hospitals
                13.2.2. Cancer Research Institutes
                13.2.3. Multispecialty Clinics
                13.2.4. Ambulatory Surgical Centers
         13.3. Middle East and Africa Kaposi Sarcoma Market, by Country, (US$), 2014–2024
                13.3.1. U.A.E.
                13.3.2. South African Republic 
                13.3.3. Rest of Middle East and Africa
         13.4. Market Attractiveness, by Type of Treatment, 2015
         13.5. Market Attractiveness, by Country, 2015

    14. Global Kaposi Sarcoma Market Analysis, By Services
         14.1. Radiation Therapy
         14.2. Surgery 

    15. Competitive Landscape
         15.1. Growth-Share Matrix of Companies, 2015
         15.2. Market Share Analysis, 2015
         15.3. Company Profiles
                15.3.1. Bristol-Myers Squibb Company
                        15.3.1.1. Company Overview
                        15.3.1.2. Business Overview
                        15.3.1.3. Product Portfolio
                        15.3.1.4. Financial Overview
                        15.3.1.5. Recent Developments
                15.3.2. Eli Lilly and Company
                        15.3.2.1. Company Overview
                        15.3.2.2. Business Overview
                        15.3.2.3. Product Portfolio
                        15.3.2.4. Financial Overview
                        15.3.2.5. Recent Developments
                15.3.3. F. Hoffmann-La Roche Ltd.
                        15.3.3.1. Company Overview
                        15.3.3.2. Business Overview
                        15.3.3.3. Product Portfolio
                        15.3.3.4. Financial Overview
                        15.3.3.5. Recent Developments
                15.3.4. GlaxoSmithKline plc
                        15.3.4.1. Company Overview
                        15.3.4.2. Business Overview
                        15.3.4.3. Product Portfolio
                        15.3.4.4. Financial Overview
                        15.3.4.5. Recent Developments
                15.3.5. Johnson & Johnson
                        15.3.5.1. Company Overview
                        15.3.5.2. Business Overview
                        15.3.5.3. Product Portfolio
                        15.3.5.4. Financial Overview
                        15.3.5.5. Recent Developments
                15.3.6. Merck & Co., Inc.
                        15.3.6.1. Company Overview
                        15.3.6.2. Business Overview
                        15.3.6.3. Product Portfolio
                        15.3.6.4. Financial Overview
                        15.3.6.5. Recent Developments
                15.3.7. Pfizer, Inc.  
                        15.3.7.1. Company Overview
                        15.3.7.2. Business Overview
                        15.3.7.3. Product Portfolio
                        15.3.7.4. Financial Overview
                        15.3.7.5. Recent Developments

    16. Recommendations

    List of Tables

    Table 1 Global Kaposi Sarcoma Market, By Type of Treatment Snapshot (2014 - 2024)
    Table 2 Global Market, By Distribution Channel, Snapshot (2014 - 2024)
    Table 3 Global Market, By Geography Snapshot (2014 - 2024)
    Table 4 Global Market, by Type of Treatment, (US$ Mn), 2014–2024
    Table 5 Global Market, by Distribution Channel, (US$ Mn), 2014–2024
    Table 6 Global Kaposi Sarcoma Market, by Region, (US$ Mn), 2014–2024
    Table 7 Pipeline Analysis
    Table 8 North America Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
    Table 9 North America Market, by Distribution Channel, (US$), 2014–    2024
    Table 10 North America Market, by Country, (US$), 2014–2024
    Table 11 Europe Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
    Table 12 Europe Market, by Distribution Channel, (US$), 2014–2024
    Table 13 Europe Market, by Country, (US$), 2014–2024
    Table 14 Asia Pacific Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
    Table 15 Asia Pacific Market, by Distribution Channel, (US$), 2014–2024
    Table 16 Asia Pacific Market, by Country, (US$), 2014–2024
    Table 17 Latin America Kaposi Sarcoma Market, by Type of Treatment (US$), 2014–2024
    Table 18 Latin America Market, by Distribution Channel (US$), 2014–2024
    Table 19 Latin America Market, by Country (US$), 2014–2024
    Table 20 Middle East & Africa Kaposi Sarcoma Market, by Type of Treatment, (US$), 2014–2024
    Table 21 Middle East & Africa Market, by Distribution Channel, (US$), 2014–2024
    Table 22 Middle East & Africa Market, by Country, (US$), 2014–2024
    Table 23 Radiotherapy and Surgery (Average cost and Number of procedures)

    List of Figures

    Figure 1 Market Segmentation
    Figure 2 Global Kaposi Sarcoma Market Revenue by Type of Treatment, (US$ Mn), 2014–2024
    Figure 3 Global Market Revenue, by Distribution Channel, (US$ Mn), 2014–2024
    Figure 4 Global Market Revenue, by Geography, (US$ Mn), 2014–2024
    Figure 5 Value Chain Analysis
    Figure 6 Global Liposomal Anthracyclines Market for Kaposi Sarcoma, (US$ Mn), 2014–2024
    Figure 7 Global Alkaloids Market, (US$ Mn), 2014–2024
    Figure 8 Global Kaposi Sarcoma Market Attractiveness, by Treatment, 2015
    Figure 9 Global Market Attractiveness, by Distribution Channel, 2015
    Figure 10 Global Market Attractiveness, by Region, 2015
    Figure 11 North America Kaposi Sarcoma Market Attractiveness, by Type of Treatment, 2015
    Figure 12 North America Market Attractiveness, by Country, 2015
    Figure 13 Europe Kaposi Sarcoma Market Attractiveness, by Treatment, 2015
    Figure 14 Europe Market Attractiveness, by Country, 2015
    Figure 15 Asia Pacific Kaposi Sarcoma Market Attractiveness, by Type of Treatment, 2015
    Figure 16 Asia Pacific Kaposi Sarcoma Market Attractiveness, by Country, 2015
    Figure 17 Latin America Market Attractiveness, by Type of Treatment, 2015
    Figure 18 Latin America Market Attractiveness, by Country, 2015
    Figure 19 Middle East and Africa Kaposi Sarcoma Market Attractiveness, by Treatment, 2015
    Figure 20 Middle East and Africa Market Attractiveness, by Country, 2015
    Figure 21 Growth Share Matrix, By Key Players (2015)
    Figure 22 Market Share Analysis by Key Companies (Value %), 2015
    Figure 23 Bristol-Myers Squibb Company Financial Overview (US$ Mn), 2013–2015
    Figure 24 Bristol-Myers Squibb Company Revenues by Segment, 2015 (%)
    Figure 25 Eli Lilly and Company Financial Overview (US$ Mn), 2013–2015
    Figure 26 Eli Lilly and Company Human Pharmaceutical Products sub-segment revenues 2015 (%)
    Figure 27  F. Hoffmann-La Roche Ltd. Financial Overview (US$ Mn), 2013–2015
    Figure 28 F. Hoffmann-La Roche Ltd. Pharmaceutical sub-segment revenues 2015 (%)
    Figure 29 GlaxoSmithKline plc Financial Overview (US$ Mn), 2013–2015 
    Figure 30 Johnson & Johnson Financial Overview (US$ Mn), 2013–2015
    Figure 31 Johnson & Johnson Pharmaceutical sub-segment revenues, 2015 (%)
    Figure 32 Merck & Co., Inc. Financial Overview (US$ Mn), 2013–2015
    Figure 33 Merck & Co., Inc. Pharmaceutical sub-segment revenues, 2015 (%)
    Figure 34 Pfizer, Inc. Financial Overview (US$ Mn), 2013–2015
    Figure 35 Pfizer, Inc. Global Vaccines, Oncology, and Consumer Healthcare sub-segment Revenues 2015 (%)

Copyright © Transparency Market Research, Inc. All Rights reserved

Kaposi Sarcoma Market

Schedule a Call